Stereotactic boost irradiation for targets in the abdomen and pelvis

Based on the experience of stereotactic irradiation of lung and liver tumors the feasibility of stereotactic boost irradiation to abdominal and pelvic tumors was evaluated. Twenty-one patients with inoperable tumors received a stereotactic boost of 2-3 x 5Gy/PTV-enclosing-100% isodose with normalization to 150% at the isocenter after normofractionated irradiation of 45-50.4Gy. Actuarial local control (16/21 targets) was 96/70% after 12 and 24 months. Treatment was feasible and well tolerated.